BridgeBio Pharma, Inc.BBIONASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+57.1%
5Y CAGR+30.7%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+57.1%/yr
vs +34.6%/yr prior
5Y CAGR
+30.7%/yr
Recent acceleration
Acceleration
+22.5pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
3.8x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$555.14M+92.1%
2024$288.93M+91.9%
2023$150.59M+5.2%
2022$143.19M-25.5%
2021$192.21M+31.9%
2020$145.68M+54.4%
2019$94.35M+116.5%
2018$43.59M+227.7%
2017$13.30M-